A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older Participants (60 to 79 Years Inclusive).
Latest Information Update: 22 Apr 2025
At a glance
- Drugs V 330 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 17 Feb 2025 The protocol has been amended to addition in treatment arm and changes in primary endpoint with change in study time frame.
- 17 Feb 2025 Planned number of patients changed from 170 to 245.
- 17 Feb 2025 Planned End Date changed from 17 Jan 2027 to 25 Jan 2027.